Abstract
The aim of this study was to develop a solid dosage form for pediatric application. For this purpose, hyaluronic acid was covalently linked with sulfhydryl groups of cysteine ethyl ester via amide bond formation mediated by carbodiimide. The obtained hyaluronic acid-cysteine ethyl ester was characterized in terms of degree of substitution, stability, mucoadhesive as well as mucoprotective and lubricative properties. Moreover, toxicity was evaluated on head and neck squamous cells as well as histology assay was performed via alcian blue staining. A novel solid dosage form was prepared and tested for its suitability for pediatric intraoral use. Obtained findings revealed sulfhydryl linked hyaluronic acid was safe to use as no irritation was detected on buccal mucosa. Stability assessment as disintegration and erosion of the matrix could be 12.0-fold and 5.23-fold in presence of hyaluronic acid-cysteine ethyl ester, respectively. The novel designed solid dosage forms provided 3.4-fold augmented lubrication in the intraoral cavity compared to respective hyaluronic acid. In conclusion, the delivery of drugs to children is still an unmet challenge to tackle. This novel excipient for smart dosage forms will pave the pathway for children's compliance to the next level of therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
